Spotlight
Clinical Role
Clinical
Supplement Spotlight
CE
Subscribe
Press Release
Article
Camber Pharmaceuticals Announces Addition of Sirolimus Oral Solution
Key Takeaways
- Sirolimus Oral Solution is indicated for organ rejection prophylaxis in renal transplant patients aged 13 and older.
- Low to moderate risk patients should initially use it with CsA and corticosteroids, withdrawing CsA 2 to 4 months post-transplant.
Camber Pharmaceuticals is excited to announce the addition of Sirolimus Oral Solution.
Sirolimus Oral Solution is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in patients aged greater or equal to 13 years receiving renal transplants.
- Patients at low to moderate immunologic risk: use initially with cyclosporine (CsA) and corticosteroids. CsA withdrawal is recommended 2 to 4 months after transplantation.
- Patients at high immunologic risk: use in combination with CsA and corticosteroids
Sirolimus Oral Solution 1 mg/mL is now available in a 60 mL bottle.
To find out more information on Sirolimus Oral Solution, please visit: www.camberpharma.com/sirolimus
Related Videos
Related Content
